Aug 14, 2024
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Aug 07, 2024
Immutep to Participate in Upcoming Investor Conferences
Jul 31, 2024
Immutep Quarterly Activities Report Q4 FY24
Jul 21, 2024
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Jul 17, 2024
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
